Welcome to our dedicated page for ODT news (Ticker: ODT), a resource for investors and traders seeking the latest updates and insights on ODT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ODT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ODT's position in the market.
Odonate Therapeutics, Inc. (NASDAQ: ODT) reported financial results for Q3 and nine months ended September 30, 2020. Cash increased to $188.3 million from $180.5 million, primarily due to $87.4 million from a public offering, offset by $81.6 million in operating losses. The company incurred a net loss of $30.5 million for Q3 and $94.1 million for the nine months, compared to losses of $26.6 million and $84.0 million in 2019. Positive results from the Phase 3 CONTESSA study of tesetaxel for metastatic breast cancer were announced, with a New Drug Application planned for mid-2021.
Odonate Therapeutics announced that results from the CONTESSA Phase 3 study of tesetaxel in metastatic breast cancer will be presented at the 2020 SABCS on December 11, 2020. The study compares tesetaxel with capecitabine in patients with HER2-negative, hormone receptor-positive metastatic breast cancer previously treated with taxane. CONTESSA aims to demonstrate progression-free survival (PFS) and assess secondary endpoints including overall survival (OS) and objective response rate (ORR). Tesetaxel showcases unique pharmacologic advantages, such as oral administration and significant antitumor activity.